GALE News 1.80 Galena Biopharma (GALE)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Galena Biopharma (GALE) 1.80 $GALE

Hagens Berman: Galena Biopharma Investigation Proceeds in Light of May 5, 2014 Lead Plaintiff Deadline in Securities Fraud Class Actions
PR Newswire - Wed Apr 16, 6:56PM CDT
Hagens Berman Sobol Shapiro LLP an investor-rights law firm with offices in San Francisco has intensified its investigation on behalf of Galena Biopharma, Inc. (NASDAQ: GALE) ("Galena" or "the Company" in light of the May 5, 2014 deadline to file for lead plaintiff in the securities fraud cases against the company. Investors who purchased Galena stock between May 9, 2013 and March 17, 2014 (the "Class Period" can contact Hagens Berman Partner Reed Kathrein, who is leading the firm's investigation, by calling 510-725-3000, emailing Galena@hbsslaw.com or visiting http://hb-securities.com/investigations/Galena.

Valuation Doesn't Equal Share Price (and That Goes Double for Biotech)
Brian Orelli, The Motley Fool - Motley Fool - Mon Apr 14, 6:52PM CDT
Most investors realize that share price is meaningless when comparing companies. A company at $50 per share might actually be worth more than a company at $100 per share because a company's value is determined by the number of outstanding shares in...

Lieff Cabraser Reminds Galena Biopharma, Inc. Investors of Upcoming Deadline in Class Action Litigation - GALE
Business Wire - Fri Apr 11, 5:28PM CDT
Lieff Cabraser Heimann & Bernstein, LLP reminds investors of the May 5, 2014 deadline to move for appointment as lead plaintiff in the securities class litigation brought on behalf of those who purchased or otherwise acquired the securities of Galena Biopharma, Inc. ("Galena" or the "Company" (Nasdaq:GALE) between May 9, 2013 and March 17, 2014, inclusive (the "Class Period" .

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Galena Biopharma, Inc. and Certain Officers - GALE
PR Newswire - Fri Apr 11, 3:14PM CDT
Pomerantz LLP has filed a class action lawsuit against Galena Biopharma, Inc. ("Galena" or the "Company" (NASDAQ: GALE) and certain of its officers. The class action, filed in United States District Court, District of Oregon, and docketed under 3:14-cv-00410-HZ, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired Galena securities between March 12, 2013 and February 11, 2014, both dates inclusive (the "Class Period" . This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws pursuant to Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder.

GALENA BIOPHARMA, INC. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of Class Action Against GALENA BIOPHARMA, INC. and Its Board and a Lead Plaintiff Deadline of May 5, 2014 -- GALE
Business Wire - Thu Apr 10, 11:15AM CDT
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of Oregon on behalf of holders of Galena Biopharma, Inc. ("Galena" or the "Company" (Nasdaq: GALE) securities between November 6, 2013 and February 14, 2014.

SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 from Investment in Galena Biopharma, Inc. to Contact Brower Piven Before the May 5, 2014 Lead Plaintiff Deadline
Business Wire - Wed Apr 09, 4:14PM CDT
Brower Piven, A Professional Corporation announces that a class action lawsuit has been commenced in the United States District Court for the District of Oregon on behalf of purchasers of Galena Biopharma, Inc. ("Galena" or the "Company" (Nasdaq: GALE) common stock during the period between November 6, 2013 and February 14, 2014, inclusive (the "Class Period" .

Financial Results Schedules, Approvals, Appointments, Product Launches, and Stock Movements - Analyst Notes on Allergan, Accuray, Cerus, Galena Biopharma, and ZELTIQ Aesthetic
PR Newswire - Wed Apr 09, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Allergan Inc. (NYSE: AGN), Accuray Incorporated (NASDAQ: ARAY), Cerus Corporation (NASDAQ: CERS), Galena Biopharma, Inc. (NASDAQ: GALE), and ZELTIQ Aesthetics, Inc. (NASDAQ: ZLTQ). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

Hagens Berman Notifies Investors of Extended Class Period and May 5, 2014 Lead Plaintiff Deadline in Galena Biopharma, Inc. Securities Fraud Class Actions
PR Newswire - Mon Apr 07, 4:23PM CDT
Hagens Berman Sobol Shapiro LLP reminds investors of the May 5, 2014 deadline to file for lead plaintiff in a securities fraud case against Galena Biopharma, Inc. (NASDAQ: GALE) ("Galena" or "the Company" . The Class Period has been extended to cover investors who bought stock between May 9, 2013 and March 17, 2014 (the "Class Period" . Investors who purchased Galena securities during the Class Period may contact Hagens Berman Partner Reed Kathrein, who is leading the firm's investigation, by calling 510-725-3000, emailing Galena@hbsslaw.com or visiting http://hb-securities.com/investigations/Galena.

INVESTOR ALERT: Glancy Binkow & Goldberg LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Lawsuit Against Galena Biopharma, Inc.
Business Wire - Thu Apr 03, 12:03PM CDT
Glancy Binkow & Goldberg LLP reminds investors of Galena Biopharma, Inc. ("Galena" or the "Company" (NASDAQ:GALE) that all purchasers of Galena securities between November 6, 2013 and February 14, 2014, inclusive (the "Class Period" , have until May 5, 2014, to file a motion to be appointed as lead plaintiff in the shareholder lawsuit.

Galena Biopharma to Present at the 13th Annual Needham Healthcare Conference
GlobeNewswire - Thu Apr 03, 6:05AM CDT
Galena Biopharma (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, today announced that Mark J. Ahn, Ph.D., President and Chief Executive Officer will present a corporate update at the 13th Annual Needham Healthcare Conference. The presentation will take place on Tuesday, April 8, 2014 at 8:40 a.m. ET at the Westin Grand Central Hotel in New York, NY.

FDA Panel Grants Market Approval of MannKind Corp.'s Inhalable Insulin
ACCESSWIRE - Wed Apr 02, 8:49AM CDT
On Apr. 1, MannKind Corp. (NASDAQ:MNKD) announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the FDA voted 13 to 1 to recommend that Afrezza, its inhalable insulin, be granted marketing approval by the FDA to improve glycemic control in adults with type 1 diabetes.

Morning Analysis on Top Gainers -- Research on Teva Pharmaceutical Industries, Capstone Turbine, Cigna, and Galena Biopharma
PR Newswire - Tue Apr 01, 8:29AM CDT
The US markets saw a positive sentiment on Monday, March 31, 2014, with the NASDAQ Composite closing at 4,198.99, up 1.04%, the Dow Jones Industrial Average ending the session at 16,457.66, up 0.82% and the S&P 500 edging 0.79% higher to finish the trading session at 1,872.34. The gains were broad based as nine out of 10 sectors ended the session in positive. A number of stocks saw large movements, including Teva Pharmaceutical Industries Ltd (NYSE: TEVA), Capstone Turbine Corp. (NASDAQ: CPST), Cigna Corp. (NYSE: CI) and Galena Biopharma Inc. (NASDAQ: GALE). Free technical research on TEVA, CPST, CI and GALE can be downloaded upon signing up at:

Hagens Berman Reminds Galena Biopharma, Inc. Investors of May 5, 2014, Lead Plaintiff Deadline and Continued Securities Fraud Investigation
Business Wire - Mon Mar 31, 12:37PM CDT
Hagens Berman Sobol Shapiro LLP reminds investors of the May 5, 2014, deadline to file for lead plaintiff in a securities fraud case against Galena Biopharma, Inc. (NASDAQ: GALE) ("Galena" or "the Company" . Investors who bought Galena securities between Nov. 6, 2013, and Feb. 14, 2014 (the "Class Period" , can contact Hagens Berman Partner Reed Kathrein, who is leading the firm's investigation, by calling 510-725-3000, emailing Galena@hbsslaw.com or by visiting http://hb-securities.com/investigations/Galena.

Today's Dead Cat Bounce Stock: Galena Biopharma (GALE)
at The Street - Mon Mar 31, 8:49AM CDT
Trade-Ideas LLC identified Galena Biopharma (GALE) as a "dead cat bounce" (down big yesterday but up big today) candidate

3 Horrendous Health-Care Stocks This Week
Keith Speights, The Motley Fool - Motley Fool - Sat Mar 29, 7:00AM CDT
Spring might have sprung this week, but plenty of investors aren't feeling warm and fuzzy. That's especially the case for shareholders of this week's three horrendous health0care stocks. One of these stocks disappointed the market by simply...

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Galena Biopharma, Inc. of Class Action Lawsuit and Upcoming Deadline -- GALE
GlobeNewswire - Fri Mar 28, 1:11PM CDT
Pomerantz LLP has filed a class action lawsuit against Galena Biopharma, Inc. ("Galena" or the "Company" (Nasdaq:GALE) and certain of its officers. The class action, filed in United States District Court, District of Oregon, and docketed under 3:14-cv-00410-HZ, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired Galena securities between March 12, 2013 and February 11, 2014, both dates inclusive (the "Class Period" . This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws pursuant to Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder.

Cohen Milstein Sellers & Toll PLLC Announces the Investigation of Galena Biopharma, Inc.
Business Wire - Fri Mar 28, 8:49AM CDT
Cohen Milstein Sellers & Toll PLLC is conducting an investigation to determine whether Galena Biopharma, Inc. ("GALE" or the "Company" and certain of its officers and directors made false and misleading statements and/or omissions in violation of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.

These Stocks Are Getting Hit Hardest During March's Biotech 'Correction'
at The Street - Tue Mar 25, 1:35PM CDT
Geron, Celldex Therapeutics, Xoma and Cytrx are among the drug stocks losing more than 30% of their value in the past month.

Galena Biopharma, Inc. Stockholders Encouraged to Contact Securities Law Firm about Investigation
PR Newswire - Mon Mar 24, 6:37PM CDT
Securities lawyers at Deans & Lyons announce an investigation of the board of Galena Biopharma, Inc. (NasdaqCM:GALE). Concerned GALE investors who purchased between November 6, 2013 and February 14, 2014 are encouraged to contact securities attorney Hamilton Lindley by clicking here.

/C O R R E C T I O N -- Robbins Arroyo LLP/
PR Newswire - Mon Mar 24, 3:18PM CDT
In the news release, Attention CytRx Corporation Investors: CytRx Misled Investors According to a Recently Filed Class Action, issued 21-Mar-2014 by Robbins Arroyo LLP over PR Newswire, we are advised by the company that the third paragraph should read that Steven A. Kriegsman sold $2.1 million of Galena Biopharma, Inc. shares, not CytRx shares as originally issued. The complete, corrected release follows:
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Norris Lake's New Kayak Fleet Propels Tourism Efforts

Updated Category News Views 157

Norris Lake Doubles Down on Water Adventures The winds of change are paddling through Norris Dam State Park as they've launched a new fleet of shiny kayaks, hoping to lure more adventure seekers into the heart of Tennessee. These ain't just boats; they're part of a bigger play by local tourism honchos hungry to pump some adrenaline—and dollars—back into the area. A...

Continue Reading
AdMaven's Mave AI: Revolutionizing Campaign Management

Updated Category News Views 161

Taking the Tedious Out of Advertising You've got to love it when technology actually makes life easier, rather than more complicated. AdMaven's latest fancy toy, the AI assistant Mave, is promising just that. It's designed to take the heavy lifting off advertisers' shoulders, especially the day-to-day grind of tweaking ad settings and monitoring performance. If you've...

Continue Reading
LA Hospitals Shine in Pulmonary Excellence Nationwide

Updated Category News Views 135

Los Angeles Community Hospitals' Recent Recognition You ever stroll into a hospital and wonder if you’re really getting the best care? Well, the folks over at Los Angeles Community Hospitals, covering LA, Norwalk, and Bellflower, just got a big nod from Healthgrades—yeah, the site everyone's checking to find decent healthcare options. They’ve landed among the top...

Continue Reading
Ross Pools Joins Forces with Florida Panthers in 2026

Updated Category News Views 69

An Unlikely Team-Up: Pools and Hockey Well, here's one for the books: a South Florida pool company hitching its wagon to an NHL team. Ross Pools, the folks who’ve been carving out backyard oases in the sizzling Florida sun for over two decades, are now officially aligned with the Florida Panthers. Yeah, the same Panthers that snatched the Stanley Cup not once but twice...

Continue Reading
Quantum X and Everest Cloud Partner in South Asia Push

Updated Category News Views 87

An Unlikely Alliance for Cutting-Edge Tech You gotta admit, the fusion of a U.S.-based tech outfit with a Nepalese cloud provider wasn't the market move anyone saw coming. But here we are—Quantum X is hitching its quantum computing dreams to Everest Cloud's solid local foothold across six South Asian markets. We're talking Nepal, India, Bangladesh, Bhutan, Sri Lanka,...

Continue Reading
Portillo's Faces Legal Heat: Investor Class Action Filed

Updated Category News Views 183

What’s Eating Portillo's? Ah, once upon a misstep in the land of promising expansion, now we have Portillo's Inc. (NASDAQ: PTLO) neck-deep in legal hot water. Those golden fries and famous sandwiches somehow didn't pave the way for stockholder bliss. Why the turmoil? On an ordinary November morning, the DJS Law Group made it clear: They're rallying the troops for a...

Continue Reading
Scientific Games Joins NCPG’s 2026 Campaign Again

Updated Category News Views 242

Scientific Games Backs Responsible Gaming Again It's another year, and here's Scientific Games once more, guns blazing for a cause that's needed more than a few times over—responsible gambling. Those folks got their hearts in the right place, joining the National Council on Problem Gambling's 2026 Gift Responsibly campaign. Ninth time running, no less! It's like...

Continue Reading
Loyalty Programs Cut $1500 Annually for Consumers

Updated Category News Views 132

Loyalty Programs: An Essential Tool for Households In a world where every dollar counts, retail loyalty programs have become more than just a marketing strategy—they're lifelines for American households scraping through each month. According to fresh research by the Retail Industry Leaders Association (RILA) and conducted by market research leader Circana, these...

Continue Reading
Gwen Stefani Kicks Off OCVIBE's New Concert Hall

Updated Category News Views 217

A Homecoming Steeped in Nostalgia Orange County’s about to do a serious throwback, folks! Gwen Stefani is set to headline the opening concert at OCVIBE's spanking new concert hall in Anaheim on March 17, 2027. Curious choice for their opener? Hardly. This gal's practically woven into the county’s tapestry—her roots run deep here, enough to make even the casual music...

Continue Reading
Crocs to Present at Key Industry Conferences

Updated Category News Views 148

Crocs Set to Step into the Spotlight Alright, if there's one thing about Crocs, Inc. (NASDAQ: CROX) that never fails to surprise, it's how they constantly keep everyone on their toes. The iconic casual footwear brand with its whimsical, love-it-or-hate-it reputation is strapping in for not one but two hefty conferences. They've circled November 19 and December 1, 2026, on...

Continue Reading

Top 5 Most Recently Viewed Articles

Compugen's Q4 2025 Results: Is CGEN Set for a Rebound?

Updated Category News Views 168

Compugen Ltd. (NASDAQ: CGEN) is gearing up for its fourth quarter and full-year 2025 financial results set to drop on March 2, 2026, before U. S. markets open. You know how it goes—traders are already sizing up this number drop, trying to parse out if there’s any upside left or if it's just another 'waiting for Godot' situation. Compugen has been riding the waves of...

Continue Reading
Procyon Partners Appoints Rich Franchella to Propel Growth Strategy

Updated Category News Views 384

Procyon Partners' Strategic Growth Through Leadership Appointment Procyon Partners is excited to announce a significant addition to its leadership team with the appointment of Rich Franchella as the Senior Vice President of Business Development. This newly established role is aimed at catalyzing the firm’s growth trajectory and is set to bolster its efforts in...

Continue Reading
SMC Entertainment Expands Horizons With Bateau Acquisition

Updated Category News Views 162

SMC Entertainment Enhances Its Market Position SMC Entertainment, Inc. has taken a significant step in broadening its reach within the financial services sector by acquiring Bateau Asset Management. This strategic move paves the path for SMC to tap into the Australian and Southeast Asian markets, expanding its footprint in the dynamic world of fintech. An Overview of...

Continue Reading
Dustin Moskovitz Expands Asana Holdings with Major Purchase

Updated Category News Views 503

Dustin Moskovitz Expands His Investment in Asana Facebook co-founder Dustin A. Moskovitz, who currently holds the position of Director at Asana, Inc., has recently made headlines by increasing his stake in the company through the acquisition of 225,000 shares. This move highlights his ongoing commitment to the growth and success of Asana. Details of the Share Purchase The...

Continue Reading
GDMining's Innovative Cloud Mining Service Redefines Accessibility

Updated Category News Views 146

GDMining Expands Global Reach with Free Cloud Mining Service The cryptocurrency market is constantly evolving, and GDMining is leading the charge. This innovative platform offers an exciting opportunity for individuals around the globe to earn income from home through its unique cloud mining services. What sets this initiative apart is that it requires no initial...

Continue Reading